July 23rd 2024
AIC100 now has a regenerative medicine advanced therapy designation from the FDA for the treatment of recurrent anaplastic thyroid cancer.
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Worden Reviews Positive Data of Cabozantinib in RAI-Refractory DTC
October 26th 2023In an interview with Targeted Oncology, Francis P. Worden, MD, discussed data from the COSMIC-311 study which support treatment with cabozantinib for patients with radioiodine-refractory differentiated thyroid cancer.
Read More
Selpercatinib Shows Superior Efficacy Vs Multikinase Inhibitors in Advanced RET+ MTC
October 21st 2023A trial comparing selpercatinib with cabozantinib or vandetanib led to greater benefit and favorable safety in the selpercatinib arm, supporting use of the selective RET inhibitor as first-line treatment for patients with advanced RET-mutant medullary thyroid cancer, according to interim data presented at the 2023 ESMO Congress.
Read More
TKIs Continue to Improve the Treatment Paradigm for RAI-Refractory DTC
July 24th 2023In an interview with Targeted Oncology, Warren C. Swegal, MD, takes a deep dive into the radioactive iodine-refectory differentiated thyroid cancer treatment armamentarium, and predicts the role of key agents in the near future.
Read More
Anaplastic Thyroid Cancer: Hope Emerges Amid Widening Range of New Therapies
June 14th 2023Though scientific advances have been encouraging in the thyroid cancer space, there is much more work to be done to figure out exactly how to tailor the right therapy, or combination of therapies, for individual patients.
Read More
Updated Eligibility Criterion Warranted in Clinical Trials of Patients With ATC
April 11th 2023In a study performed at MD Anderson Cancer Center, there was no significant overall survival impact in patients with anaplastic thyroid cancer who had prior differentiated thyroid cancer, concomitant differentiated thyroid cancer, and prior non thyroid cancers.
Read More
Molecular Targets Making Headway in Pediatric Thyroid Cancer Research
March 16th 2023In an interview with Targeted Oncology, Aime T. Franco, PhD, discussed the molecular landscape of pediatric patients with thyroid cancer and the presentation she gave at the 91st Annual Meeting of the American Thyroid Association.
Read More
Precision Oncology Inches into Head and Neck Cancer Paradigm
February 4th 2023In an interview with Targeted Oncology, Everett E. Vokes, MD, discussed precision oncology for head and neck cancer and how the molecular biology of head and neck cancers is an opportunity for new investigations and treatment development.
Read More
Survivorship and Quality-of-Life Play Important Roles for Patients With Thyroid Cancer
January 24th 2023In an interview with Targeted Oncology, Melanie Goldfarb, MD, MSc, FACS, FACE, highlighted the importance of long-term survivorship care and the quality-of-life aspects of patients with thyroid cancer.
Read More
The Impact of Molecular Alterations in Advanced RAI-R-DTC Treatment Decision-Making
January 17th 2023Lori Wirth, MD, explains why the importance of molecular alterations in her treatment decision-making for a patient with advanced RAI-R-DTC, and the other factors she considers for an appropriate treatment.
Watch